Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Corcept Therapeutics Inc. is projected to achieve significant sales growth, with annual Korlym sales forecasted to increase by 19% to 26% year-over-year, reaching between $800 million and $850 million in FY2025. This growth is supported by strong underlying demand, as volume has grown over 40% in the last two quarters, indicating the company's effective market execution despite recent challenges. Furthermore, the promising results from clinical trials involving relacorilant, particularly in advanced cancer treatments, suggest a robust pipeline and potential for expansion into broader indications, reinforcing confidence in the company's growth trajectory.

Bears say

Corcept Therapeutics's stock outlook is negatively impacted by a recent Complete Response Letter (CRL) that suggests delays in the launch of relacorilant for Cushing’s Syndrome, prompting a significant reduction in the 12-month price target from $145 to $90 per diluted share. The company's stock price fell by approximately 50.4%, closing at around $35, reflecting market apprehension related to commercial distribution changes and anticipated softness in upcoming financial performance. Despite management's previous success in drug launches, the substantial drop in projected revenues and the market's reaction to news from the company raise concerns about future profitability and growth potential.

Corcept Therapeutics (CORT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Buy based on their latest research and market trends.

According to 5 analysts, Corcept Therapeutics (CORT) has a Buy consensus rating as of Jan 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $111, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $111, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.